GSK stock moves sideways after net debt rise from investments and buybacks

Traders Union
All News
Financial News
GSK up 0.10% after Q1 earnings beat

Highlights

GSK outperformed expectations in Q1 2026 with core EPS of 46.5 pence, driven by strong HIV and oncology treatment sales and disciplined cost management.
Core operating profit rose 10% to £2.65 billion and the company reaffirmed its full-year outlook, maintaining a 17 pence dividend despite elevated net debt from acquisitions and buybacks.
Technically, the stock trades below key near-term trend levels with strong bearish momentum and oversold signals, consolidating between GBX 1,875 and GBX 1,975 and a low probability of near-term upside.

Earnings beat and specialty drug growth drive optimism despite higher debt

GSK’s first quarter 2026 results showed core earnings per share at 46.5 pence, beating analyst expectations and highlighting effective cost control with robust revenue growth. Revenue increased 5% on a constant currency basis to £7.6 billion, primarily driven by strong sales of HIV and cancer treatments, while core operating profit rose 10% to £2.65 billion. The company maintained its shareholder focus by declaring a 17 pence dividend and reaffirming full-year guidance, with recent acquisitions strengthening its specialty medicines pipeline. Meanwhile, an increase in net debt was reported, mainly tied to strategic investments, dividends, and share buybacks.

Bearish momentum dominates as trading holds below key resistance

On the technical charts, GSK is trading below the MA-20 (GBX 2,099.80) and MA-50 (GBX 2,094.90), while holding above the MA-200 (GBX 1,783.96). The Ichimoku Kijun level at GBX 2,027.50 acts as immediate resistance for any near-term upside, anchoring short-term trading. Momentum signals, including MACD and ADX, remain in bearish territory on the daily timeframe, with the RSI showing a weak reading of 29.7. Stoch RSI and CCI are oversold, while a sharply negative BBP and bearish Awesome Oscillator point to dominant seller pressure even as oscillators suggest possible exhaustion.

Low rebound probability as oversold signals limit downside risk

In the short term, GSK is expected to trade within a typical volatility band of GBX 1,875–1,975 over the next five sessions. The probability of a meaningful upward move remains low, with continued consolidation and a bias for marginal declines likely. Should the price break above immediate resistance at GBX 2,027.50, a short-term rebound targeting higher resistance zones could develop. However, a sustained move below GBX 1,875 would signal further downside, though the oversold conditions may limit the intensity of additional declines.

Viktoras Karapetjanc, Traders Union expert, sees GSK’s Q1 earnings beat and robust specialty medicines growth as strong fundamental positives. He notes that the reaffirmed guidance and ongoing pipeline expansion strengthen investor confidence, even as technical momentum remains weak. Karapetjanc believes recent oversold signals suggest downside is likely limited for now. Near-term, upside may be contained by resistance at GBX 2,027.50, but the constructive results keep outlook positive. "If GSK can push through the current technical resistance, the strong fundamentals could quickly bring buyers back into the market."

Earlier, analysts noted that GSK shares were under short- and medium-term selling pressure despite support from long-term fundamentals and a resilient vaccine portfolio. Ongoing technical weakness and persistent oversold readings in the current environment reinforce a cautious outlook, with any sustainable rebound hinging on a decisive break above GBX 2,027.50 resistance in the coming sessions.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.